Ron Cohen - 16 Mar 2023 Form 4 Insider Report for Acorda Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ Ron Cohen
Issuer symbol: N/A
Transactions as of: 16 Mar 2023
Net transactions value: +$12,594
Form type: 4
Filing time: 20 Mar 2023, 16:29:58 UTC
Previous filing: 21 Mar 2022
Next filing: 04 Apr 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACOR	Common Stock	Purchase	$6,094	+10,156	+7.8%	$0.6000	139,757	16 Mar 2023	Direct	F1
transaction	ACOR	Common Stock	Purchase	$6,500	+10,000	+7.2%	$0.6500	149,757	17 Mar 2023	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.590 to $0.600. The reporting person undertakes to provide to Acorda Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.590 to $0.600. The reporting person undertakes to provide to Acorda Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.